Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. Novacyt
  6. News
  7. Summary
    ALNOV   FR0010397232

NOVACYT

(ALNOV)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Novacyt S.A. Announces Executive Changes, Effective October 18, 2021

07/29/2021 | 02:00am EDT

Novacyt S.A. announced the appointment of David Allmond as CEO effective from 18 October 2021. At that time Graham Mullis, having informed the Board that he wishes to retire after 13 years with the expanded Group, will stand down as CEO. David, brings relevant leadership experience in life science companies experiencing significant development and growth, and developing businesses into new global markets. Currently he is Chief Business Officer at Amryt Pharma, where he has played a key role in developing the company into a leading global rare and orphan disease drug company. Earlier in his career David held sales and marketing roles of increasing seniority at Amgen, Celgene, and Aegerion Pharmaceuticals. David will be supported by Novacyt’s recently strengthened executive management team. Graham is committed to ensuring a smooth transition with David and will continue to lead the Group as CEO until David joins the Company.


ę S&P Capital IQ 2021
All news about NOVACYT
09/16FTSE 100 Rises on Speculation over UK's Travel Restrictions Removal
DJ
09/16GLOBAL MARKETS LIVE : Thales, Nestlé, Evergrande, AMC, Walmart...
09/16FTSE Rises, THG Shares Fall After 1st Half Loss as Shake-Up Looms
DJ
09/16NOVACYT : Dispute With UK Health Department Threatens To Wipe Out H1 Profit
MT
09/16FTSE Rises, Ashtead Gains After 1Q Profit Boost, Guidance Increase
DJ
09/16Novacyt Says Covid-19 Contract Dispute with UK Health Department Continues
DJ
09/16Novacyt to Revise Down 1st Half Revenue Due to UK Covid-19 Contract Dispute -- Update
DJ
09/16NOVACYT : Proposed accounting treatment of ongoing DHSC dispute in 2021 interim results
PU
09/13NOVACYT : AGM voting
PU
09/08NOVACYT : Company's activity during FY20
PU
More news
Financials
Sales 2021 112 M 131 M 131 M
Net income 2021 70,0 M 82,0 M 82,0 M
Net cash 2021 90,4 M 106 M 106 M
P/E ratio 2021 4,26x
Yield 2021 -
Capitalization 262 M 307 M 306 M
EV / Sales 2021 1,53x
EV / Sales 2022 0,83x
Nbr of Employees 174
Free-Float 99,0%
Chart NOVACYT
Duration : Period :
Novacyt Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVACYT
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 2
Last Close Price 3,71 €
Average target price 4,10 €
Spread / Average Target 10,6%
EPS Revisions
Managers and Directors
Graham David Mullis Chief Executive Officer & Executive Director
James Martin Mccarthy Chief Financial Officer & Director
James Christopher Wakefield Chairman
Reginald A. Trevor Chief Technology Officer
Lisa Henriet Director-Group Operations
Sector and Competitors
1st jan.Capi. (M$)
NOVACYT-62.18%307
MODERNA, INC.321.86%177 895
GILEAD SCIENCES, INC.22.52%89 497
BIONTECH SE316.17%81 938
WUXI APPTEC CO., LTD.36.63%69 841
REGENERON PHARMACEUTICALS33.94%67 273